We are live on ! Find out more
VPHM

VIROPHARMA INC
VPHM

Delisted

VPHM was delisted on the 23rd of January, 2014.

172 hedge funds and large institutions have $3.29B invested in VIROPHARMA INC in 2013 Q4 according to their latest regulatory filings, with 52 funds opening new positions, 47 increasing their positions, 61 reducing their positions, and 69 closing their positions.

New
Increased
Maintained
Reduced
Closed

175% more funds holding in top 10

Funds holding in top 10: 411 (+7)

14% more capital invested

Capital invested by funds: $2.87B → $3.29B (+$416M)

10% less funds holding

Funds holding: 191172 (-19)

23% less repeat investments, than reductions

Existing positions increased: 47 | Existing positions reduced: 61

25% less first-time investments, than exits

New positions opened: 52 | Existing positions closed: 69

57% less call options, than puts

Call options by funds: $67.1M | Put options by funds: $155M

Holders
172
Holders Change
-19
Holders Change %
-9.95%
% of All Funds
4.99%
Holding in Top 10
11
Holding in Top 10 Change
+7
Holding in Top 10 Change %
+175%
% of All Funds
0.32%
New
52
Increased
47
Reduced
61
Closed
69
Calls
$67.1M
Puts
$155M
Net Calls
-$87.5M
Net Calls Change
-$82.9M
Name Holding Trade Value Shares
Change
Change in
Stake
Renaissance Technologies
26
Renaissance Technologies
New York
$31.4M +$28.2M +630,800 New
GCIA
27
Gabelli & Co Investment Advisers
New York
$23.9M +$21.5M +479,941 New
UOC
28
UBS O'Connor
Illinois
$22.9M +$20.5M +459,122 New
Deutsche Bank
29
Deutsche Bank
Germany
$21.9M +$13.8M +308,539 +237%
Norges Bank
30
Norges Bank
Norway
$21.5M
MF
31
Magnetar Financial
Illinois
$21.1M +$17.7M +396,617 +1,464%
Ameriprise
32
Ameriprise
Minnesota
$20.4M +$6.99M +156,211 +62%
Principal Financial Group
33
Principal Financial Group
Iowa
$20M +$1.07M +23,885 +6%
MFP
34
Michael F. Price
$19.9M +$4.81M +107,500 +37%
LIM
35
Longfellow Investment Management
Massachusetts
$19.9M +$17.8M +398,350 New
DGI
36
Disciplined Growth Investors
Minnesota
$17.5M -$8.93M -199,810 -36%
TCIM
37
TIAA CREF Investment Management
New York
$16.6M +$2.19M +48,866 +17%
Geode Capital Management
38
Geode Capital Management
Massachusetts
$16.6M +$1.13M +25,357 +8%
PI
39
PineBridge Investments
New York
$15.5M +$13.6M +304,096 +4,128%
Alyeska Investment Group
40
Alyeska Investment Group
Illinois
$15M +$13.4M +300,000 New
TS
41
Twin Securities
New York
$14.9M +$12.1M +271,408 +1,024%
JP Morgan Chase
42
JP Morgan Chase
New York
$14.6M -$12.9M -289,077 -50%
PAI
43
Palo Alto Investors
California
$14.5M -$125M -2,802,375 -91%
Royal Bank of Canada
44
Royal Bank of Canada
Ontario, Canada
$14.4M +$12.6M +281,359 +3,392%
COPPSERS
45
Commonwealth of Pennsylvania Public School Employees Retirement System
Pennsylvania
$12.5M +$11.2M +250,000 New
HS
46
HighVista Strategies
Massachusetts
$11.6M +$10.4M +232,768 New
T. Rowe Price Associates
47
T. Rowe Price Associates
Maryland
$11.4M -$18M -402,000 -64%
PP
48
Paloma Partners
Connecticut
$11.2M +$10.1M +225,000 New
BIM
49
BlackRock Investment Management
Delaware
$10.8M -$64.5K -1,443 -0.7%
SCM
50
Stevens Capital Management
Pennsylvania
$10.4M +$9.29M +207,768 New

VPHM Hedge Fund Activity: Q4 2013 in Review

172 of the 3,446 institutional investors tracked by Wall St. Rank reported a position in VIROPHARMA INC (VPHM) for Q4 2013, worth a combined $3.29B — up 14% from $2.87B a quarter earlier.

Sellers outnumbered buyers: 69 funds closed out of VPHM and 52 opened new positions — a net loss of 17 holders — while 61 trimmed existing stakes and 47 added.

The largest buyer was Oxford Asset Management, opening a new position worth an estimated $137M. The largest seller was Baker Bros. Advisors, exiting entirely with an estimated $220M sold.

  • 172 institutional investors held VIROPHARMA INC (VPHM) as of Q4 2013, down from 191 in Q3 2013.
  • Funds reported $3.29B of VIROPHARMA INC stock for Q4 2013, up 14% quarter-over-quarter.
  • 52 funds opened new VIROPHARMA INC positions in Q4 2013 and 69 closed out, a net change of -17 holders.
  • The largest VIROPHARMA INC buyer in Q4 2013 was Oxford Asset Management, an estimated $137M added.
  • The largest VIROPHARMA INC seller in Q4 2013 was Baker Bros. Advisors, an estimated $220M sold.

Based on aggregated 13F filings for Q4 2013.